We use cookies to optimise this website and continuously update it according to your needs. Please click on "Configure" for detailed information on the use of cookies on this website. If you click "Yes, I agree", cookies will be activated. If you do not want cookies to be activated, you can adjust your settings by clicking on "Configure". The settings can be changed at any time under "Cookies".
During December, 103 new B shares were issued in Elekta through conversion to shares within the framework of the 2012/17 convertible bond.
The total number of shares in Elekta as of December 28, 2012, amounts to 382,807,329 divided between 14,250,000 A shares and 368,557,329 B shares.
One A share entitles the holder to ten votes and one B share to one vote.
******
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Johan Andersson Melbi, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451,
E-mail: johan.anderssonmelbi@elekta.com .